At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Psilocybindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
In Brief
A Phase 2 clinical trial evaluating Psilocybin for Treatment Resistant Depression. Completed, enrolled 19 participants across 2 sites in 2 countries.
Detailed Summary
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment Resistant Depression
CountriesIreland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartAug 2020
First PostedFeb 2021
Primary CompletionOct 2021
TodayJul 2026
First PostedFeb 5, 2021
Enrollment StartAug 10, 2020
Primary CompletionOct 14, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.4 years ago
Interventions
Psilocybindrug
Open label